Tesamorelin – Pro

Pro Series
Tesamorelin, a synthetic analogue of growth hormone-releasing hormone
CAS 218949-48-5C₂₂₁H₃₆₆N₇₂O₆₇SApproximately 5135.9 g/mol44 amino acidsLinear peptideLyophilized powder

Price range: $120.00 through $970.00

Ships from lot nhs-tsm-20260817-08 · 10 mg vial · 99% purity · pH Solutions Lab See the COA
Why the Pro Series costs more
  • Synthesized in the USA. Domestic ground and air only, no ocean freight.
  • Released only above 99% HPLC purity.
  • Its own lot and its own published certificate.
How the Pro Series is made and tested
Ships from Austin, TexasUnited States only
Tested by an outside labNever in-house
Every lot publishedIncluding rejected lots
Same-day dispatchOn orders before 2pm ET
BATCH
VERIFICATION
LOT NUMBER
nhs-tsm-20260817-08
10 mg vial
IDENTITY
Match (C221H366N72O67S, 5135.9 g/mol)
CHROMATOGRAPHIC PURITY
99%
NET CONTENT
9.9188 mg (99.188% of 10 mg label claim)
Analytical characterization

Every result against its specification.

Lot nhs-tsm-20260817-08 · 10 mg vial · pH Solutions Lab · reported 29 September 2026 . The bar shows where the reported result falls against Astramide’s published release criterion. The notch marks the criterion.
Within criterion Above criterion Not on this COA
Test
Method
Criterion
Result
Result vs criterion
Status
Identity
Match to the labelled compound
Match (C221H366N72O67S, 5135.9 g/mol)
WITHIN SPEC
Chromatographic purity
HPLC (220 nm)
at or above 99.0%
99%
95 at or above 99.0% 100
WITHIN SPEC
Net content
9.9188 mg (99.188% of 10 mg label claim)
80 120
REPORTED
Appearance
Visual
white lyophilized powder
White to off-white lyophilized powder cake, free of visible particulates
WITHIN SPEC
Water content
Karl Fischer
reported
0.757%
WITHIN SPEC
pH
reported
7.0
WITHIN SPEC
Water activity
within laboratory limit
0.4045 aw, pass
WITHIN SPEC
Microbial panel
not detected
Pass, 10 organisms and counts not detected
WITHIN SPEC
Heavy metals
within laboratory limits
Pass. As, Cd, Pb, Hg each 0.000 ppm
WITHIN SPEC
Residual solvents
within laboratory limits
Pass. Ethyl ether 5.853165 ppm, ethyl acetate 2.690704 ppm; 10 other solvents 0.000 ppm
WITHIN SPEC
Sterility
sterile
Pass
WITHIN SPEC
Mycotoxins
within laboratory limits
Pass
WITHIN SPEC
Endotoxin
LAL
—
Not reported on this certificate
NOT REPORTED
Values are reported per vial unless otherwise noted. Every figure here is taken from the batch Certificate of Analysis and nothing else.
Certificate of Analysis
Tesamorelin - Pro · Lot nhs-tsm-20260817-08 · 10 mg vial · Lab No. nhs-tsm-20260817-08
Download Full screen
Your browser cannot display the report inline. Open the PDF.
pH Solutions Lab · 4 pages · served inline, not a screenshot
Quick reference

How to read this report

Same six keys on every Astramide product page. Only the values change.
1Lot numberMatch it to the number printed on your vial. If they differ, this report is not for your vial.
2IdentityMass spectrometry confirms the molecule is the one on the label. It conforms or it does not. There is no partial result.
3Chromatographic purityThe share of the material that is the target peptide. A purity figure quoted without a method is not a purity figure.
4Net contentHow much peptide is in the vial, as measured by the laboratory. A different question from purity.
5EndotoxinMeasured against a ceiling, not a floor. Sensitivity differs by laboratory, so results are not compared across labs.
6Laboratory, method, dateWho ran it, on what instrument, and when. A report with no named laboratory or no date is not a report.
Molecular profile

Tesamorelin - Pro, in structural terms.

Tesamorelin - Pro molecular structure
Sequence
trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 (trans-3-hexenoyl-YADAIFTNSYRKVLGQLSARKLLQDIMSRQQGESNQERGARARL-NH2)
Molecular formula
C₂₂₁H₃₆₆N₇₂O₆₇S
Molecular weight
Approximately 5135.9 g/mol
CAS number
218949-48-5
Peptide length
44 amino acids
Structure type
Linear peptide
Parent sequence
Human growth hormone-releasing hormone, residues 1-44
Primary molecular target
Growth hormone-releasing hormone receptor (GHRHR), a class B G protein-coupled receptor that signals mainly through Gs, adenylyl cyclase and cAMP.
Physical form
Lyophilized powder
PubChem CID
16137828

Tesamorelin is a synthetic 44-amino-acid peptide with the full sequence of human growth hormone-releasing hormone (GHRH 1-44) and a C-terminal amide. It carries a trans-3-hexenoyl group on the N-terminal tyrosine, which is its only structural difference from native GHRH. That N-terminal acyl group was introduced to slow enzymatic cleavage at the N-terminus.

Research profile

Where Tesamorelin - Pro appears in the literature.

Endocrinology; Neuroendocrinology; Receptor Pharmacology; Peptide Chemistry; Structural Biology
Research applications
  • Published studies have used tesamorelin and GHRH analogues in:
  • GHRHR binding and activation studies
  • cAMP signaling studies
  • Comparisons of N-acylated and native GHRH stability
  • Non-clinical pharmacology in animal models
  • GHRHR structural biology
Experimental systems
  • Cell lines expressing recombinant GHRHR
  • Primary anterior pituitary cell cultures
  • Animal models used in non-clinical pharmacology studies
  • Purified GHRH-GHRHR-Gs complexes for cryo-electron microscopy
Specific assays
  • Radioligand binding assays
  • cAMP accumulation assays
  • Enzymatic stability assays
  • Serum hormone measurement in animal models
  • Cryo-electron microscopy
Measured endpoints
  • Binding affinity and functional potency at GHRHR
  • Intracellular cAMP production
  • Peptide stability against enzymatic degradation
  • Growth hormone release in animal models
  • Ligand-receptor contact residues in the GHRH-GHRHR complex
Pcs

Single Vial, Pack of 10

Strength

10mg

Mechanism and research context

What has been studied, and in what systems.

Tesamorelin is a synthetic analogue of human GHRH that keeps the full 44-residue native sequence and adds a trans-3-hexenoyl group to the N-terminus. Its target is the GHRH receptor, a class B G protein-coupled receptor whose structure and coupling to Gs and cAMP signaling have been reviewed in detail (Petersenn and Schulte, 2000).

The compound, originally coded TH9507, was characterised in a published non-clinical pharmacology and safety evaluation using in vitro systems and animal models (Ferdinandi et al., 2007).

A cryo-electron microscopy structure of GHRH bound to its receptor and Gs later showed how the N-terminal region of the peptide enters the receptor core, which is the region modified in tesamorelin (Zhou et al., 2020). These studies place tesamorelin in receptor pharmacology and peptide analogue research.

These are published research systems. They do not describe approved clinical applications, and they do not establish efficacy or safety in humans.

Cited literature

Ferdinandi ES et al., 2007. Non-clinical pharmacology and safety evaluation of TH9507, a human growth hormone-releasing factor analogue. Basic Clin Pharmacol Toxicol. PMID 17214611. https://pubmed.ncbi.nlm.nih.gov/17214611/
Petersenn S, Schulte HM, 2000. Structure and function of the growth-hormone-releasing hormone receptor. Vitam Horm. PMID 10714236. https://pubmed.ncbi.nlm.nih.gov/10714236/
Zhou F et al., 2020. Structural basis for activation of the growth hormone-releasing hormone receptor. Nat Commun. PMID 33060564. https://pubmed.ncbi.nlm.nih.gov/33060564/

Evidence level
GHRH receptor pharmacology is well characterised in binding, signaling and structural studies, and the non-clinical pharmacology of tesamorelin has been published. Statements on this page describe experimental systems, not outcomes in humans.
Handling and storage
As supplied
Lyophilized powder in a sealed vial. Held in laboratory-rated freezers from arrival to shipment.
Storage
Store per the conditions printed on the vial label. Avoid heat, moisture and repeated temperature cycling.
Handling
For qualified professionals in controlled laboratory environments, following validated laboratory procedures.
Frequently asked questions

About this compound and its batch data.

What is tesamorelin?

Tesamorelin is a synthetic 44-amino-acid analogue of human growth hormone-releasing hormone (GHRH) with a trans-3-hexenoyl group on its N-terminus and a C-terminal amide. Its molecular formula is C221H366N72O67S, its molecular weight is about 5135.9 g/mol and its CAS number is 218949-48-5. Tesamorelin Pro is supplied as a lyophilized powder in a 10 mg vial. Sold for research use only.

What has tesamorelin been examined for in published research?

Under its development code TH9507, tesamorelin was characterised in a published non-clinical pharmacology and safety evaluation using in vitro systems and animal models (Ferdinandi et al., 2007, PMID 17214611). Its target, the GHRH receptor, has been resolved by cryo-electron microscopy (Zhou et al., 2020, PMID 33060564). This work was pre-clinical. Astramide makes no claim about outcomes in humans.

What purity does the current Tesamorelin Pro lot reach?

Lot nhs-tsm-20260817-08 returned 99% chromatographic purity by HPLC at 220 nm, reported by pH Solutions Lab on 29 September 2026 under certificate 260825-899-NHS-2. Identity was confirmed as a match to tesamorelin (C221H366N72O67S, 5135.9 g/mol). The lot meets the Pro Series release criterion of at or above 99% HPLC purity. The full certificate is published on this page.

How much tesamorelin is in the vial?

The label claim is 10 mg per vial. For lot nhs-tsm-20260817-08, the laboratory measured 9.9188 mg of tesamorelin, which is 99.188% of the 10 mg label claim. Astramide publishes the measured figure exactly as the laboratory reports it, above or below the label. Net content and chromatographic purity are separate measurements.

How should tesamorelin be stored for research use?

Lyophilized tesamorelin is stored at -20°C and protected from light. Once reconstituted, the solution is held at 2 to 8°C and used within 14 to 30 days. Repeated temperature cycling and exposure to moisture should be avoided, because both can affect peptide stability and the comparability of experimental results.

How is tesamorelin different from sermorelin?

Both are synthetic peptides based on human GHRH and both act at the GHRH receptor. Sermorelin contains only residues 1 to 29 of GHRH with no added group. Tesamorelin keeps the full 44-residue sequence and adds a trans-3-hexenoyl group to the N-terminus, which was introduced to slow enzymatic cleavage (Ferdinandi et al., 2007, PMID 17214611).

How is Astramide's Tesamorelin Pro tested?

Lot nhs-tsm-20260817-08 was tested by pH Solutions Lab, an independent ISO/IEC 17025:2017 accredited laboratory (A2LA R243, PJLA Testing #84351). The certificate reports identity, chromatographic purity at 220 nm, net content, water content, pH, water activity, a 10-organism microbial panel, heavy metals, residual solvents, sterility and mycotoxins. Results apply only to this lot.

What is the difference between Tesamorelin and Tesamorelin Pro?

Tesamorelin Pro is part of the Astramide Pro Series. It is American-made, synthesized in the USA, and moves by domestic ground and air only, with no ocean freight. It is released under its own lot, and only when HPLC purity measures at or above 99%. The full certificate for each lot is published on this page. The standard Tesamorelin is released under separate lots with separate certificates.

Research use only

This product is intended strictly for in-vitro laboratory research conducted by qualified professionals. It is not intended for human or animal consumption, clinical use, or therapeutic application. The statements on this page have not been reviewed by the FDA. These research peptides are not intended to diagnose, treat, cure, or prevent any disease. Research Use Only.

Ships from Austin, TexasUSPS or UPS, your choice
United States onlyFree shipping at $150 and over
Optional shipping insuranceAdded at checkout
Replacement or store creditOn approved claims. See refund policy.